Context Therapeutics Inc. (CNTX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.67
↑+272% vs avg
5yr avg: 0.99
30Y Low0.2·High2.3
ROE
↑
-46.4%
↓+23% vs avg
5yr avg: -60.3%
30Y Low-103%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CNTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Context Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $214M | $140M | $61M | $18M | $10M | $8M | — | — |
| Enterprise Value | $148M | $74M | $-32873644 | $4M | $-25037325 | $-42096757 | — | — |
| P/E Ratio → | -6.13 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.67 | 2.31 | 0.64 | 1.52 | 0.30 | 0.16 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CNTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
CNTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -46.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -46.4% | -46.4% | -49.9% | -102.8% | -35.7% | -66.7% | — | — |
| ROA | -43.4% | -43.4% | -46.8% | -88.7% | -33.2% | -40.4% | 1793.5% | -2333.8% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -50.9% | -50.9% | -55.8% | -107.5% | -37.0% | -53.7% | — | — |
CNTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $66M exceeds total debt of $112064, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.09 | -0.99 | -1.22 | -1.02 | -1.03 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -27.19 | -161.78 | -3.89 | -4.80 |
Net cash position: cash ($66M) exceeds total debt ($112064)
CNTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Context Therapeutics Inc.'s current ratio of 8.52x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.83x to 8.52x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.52 | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 | 0.04 | 0.01 |
| Quick Ratio | 8.52 | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 | 0.04 | 0.01 |
| Cash Ratio | 8.23 | 8.23 | 34.36 | 3.45 | 11.07 | 16.36 | 0.04 | 0.01 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
CNTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Context Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $95M | $58M | $16M | $16M | $3M | $11M | $11M |
Peer Comparison
Compare CNTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CNTXYou | $214M | -6.1 | — | — | — | — | -46.4% | — | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ONCO | $1M | -0.1 | — | — | 77.6% | -778.2% | -110.6% | -32.8% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 SNDX | $2B | -6.2 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 PRME | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See CNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNTX vs AGEN
Side-by-side business, growth, and profitability comparison vs Agenus Inc..
Start ComparisonCNTX — Frequently Asked Questions
Quick answers to the most common questions about buying CNTX stock.
What is Context Therapeutics Inc.'s P/E ratio?
Context Therapeutics Inc.'s current P/E ratio is -6.1x. This places it at the 50th percentile of its historical range.
What is Context Therapeutics Inc.'s ROE?
Context Therapeutics Inc.'s return on equity (ROE) is -46.4%. The historical average is -60.3%.
Is CNTX stock overvalued?
Based on historical data, Context Therapeutics Inc. is trading at a P/E of -6.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.